Traders purchased shares of AbbVie Inc. (NYSE:ABBV) on weakness during trading on Monday. $126.22 million flowed into the stock on the tick-up and $81.85 million flowed out of the stock on the tick-down, for a money net flow of $44.37 million into the stock. Of all stocks tracked, AbbVie had the 27th highest net in-flow for the day. AbbVie traded down ($1.10) for the day and closed at $95.22
A number of equities analysts have issued reports on the company. BMO Capital Markets set a $84.00 target price on AbbVie and gave the company a “hold” rating in a research report on Monday. ValuEngine lowered AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Friday. Societe Generale upped their target price on AbbVie in a research report on Tuesday, November 21st. BidaskClub raised AbbVie from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 11th. Finally, Zacks Investment Research lowered AbbVie from a “buy” rating to a “hold” rating in a research report on Wednesday, November 1st. Seven research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. AbbVie currently has a consensus rating of “Buy” and an average price target of $96.72.
The company has a debt-to-equity ratio of 5.08, a quick ratio of 1.32 and a current ratio of 1.45. The stock has a market capitalization of $151,790.00, a price-to-earnings ratio of 18.14, a price-to-earnings-growth ratio of 1.36 and a beta of 1.53.
AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, October 27th. The company reported $1.41 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.39 by $0.02. AbbVie had a return on equity of 153.80% and a net margin of 24.38%. The business had revenue of $7 billion during the quarter, compared to the consensus estimate of $7 billion. During the same period in the previous year, the business earned $1.21 EPS. The business’s quarterly revenue was up 8.8% on a year-over-year basis. research analysts predict that AbbVie Inc. will post 5.55 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, February 15th. Stockholders of record on Friday, January 12th will be issued a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.98%. This is an increase from AbbVie’s previous quarterly dividend of $0.64. The ex-dividend date of this dividend is Thursday, January 11th. AbbVie’s payout ratio is 62.14%.
In related news, SVP Azita Saleki-Gerhardt sold 8,300 shares of the company’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $85.02, for a total transaction of $705,666.00. Following the completion of the transaction, the senior vice president now directly owns 93,099 shares in the company, valued at approximately $7,915,276.98. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Chairman Richard A. Gonzalez sold 218,193 shares of the company’s stock in a transaction on Tuesday, November 21st. The stock was sold at an average price of $94.01, for a total value of $20,512,323.93. Following the transaction, the chairman now owns 492,030 shares of the company’s stock, valued at $46,255,740.30. The disclosure for this sale can be found here. Insiders sold a total of 277,125 shares of company stock valued at $25,891,756 over the last quarter. Company insiders own 0.23% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the stock. Acropolis Investment Management LLC acquired a new position in AbbVie during the 2nd quarter worth $106,000. Franklin Parlapiano Turner & Welch LLC acquired a new position in AbbVie during the 1st quarter worth $108,000. Hudock Capital Group LLC boosted its position in AbbVie by 109.5% during the 2nd quarter. Hudock Capital Group LLC now owns 1,542 shares of the company’s stock worth $111,000 after acquiring an additional 806 shares during the period. Ffcm LLC boosted its position in AbbVie by 167.2% during the 2nd quarter. Ffcm LLC now owns 1,539 shares of the company’s stock worth $111,000 after acquiring an additional 963 shares during the period. Finally, Bristlecone Advisors LLC acquired a new position in AbbVie during the 3rd quarter worth $113,000. Hedge funds and other institutional investors own 69.32% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Traders Buy Shares of AbbVie (ABBV) on Weakness” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another website, it was stolen and reposted in violation of U.S. and international copyright and trademark legislation. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2017/12/04/traders-buy-shares-of-abbvie-abbv-on-weakness.html.
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with MarketBeat.com's FREE daily email newsletter.